AstraZeneca
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.About AZN
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology.
AZN Key Statistics
Stock Snapshot
With a market cap of 288.32B, AstraZeneca(AZN) trades at $184.62. The stock has a price-to-earnings ratio of 27.83 and currently yields dividends of 1.7%.
On 2026-03-23, AstraZeneca(AZN) stock moved within a range of $179.11 to $186.78. With shares now at $184.62, the stock is trading +3.1% above its intraday low and -1.2% below the session's peak.
Trading volume for AstraZeneca(AZN) stock has reached 1.45M, versus its average volume of 1.65M.
The stock's 52-week range extends from a low of $122.48 to a high of $212.71.
The stock's 52-week range extends from a low of $122.48 to a high of $212.71.
AZN News
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca’s new China study takes a close look at how different lab tests agree...
AstraZeneca (AZN) and Sanofi (SNY) have become the latest drugmakers in the West to expand R&D operations in China, a market with highly sought-after R&D prospe...
AstraZeneca ( (GB:AZN) ) just unveiled an announcement. AstraZeneca has admitted 45,750 additional ordinary shares of $0.25 each to trading on the London Stock...
Analyst ratings
81%
of 31 ratingsMore AZN News
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. The REVIVE study, formally titled “Biomarker-Directed Treatment in Patients Who H...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca Backs Real-World Kidney Study in China The study, titled “A Multicen...
AstraZeneca ($~AZN) announced an update on their ongoing clinical study. AstraZeneca’s EXACOS EG Population study, officially titled “Exacerbations and Their O...
Analyst Steve Scala of TD Cowen maintained a Buy rating on AstraZeneca, with a price target of $240.00. Claim 70% Off TipRanks Premium Unlock hedge fund-level d...
AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. The study “A Study to Evaluate the Accuracy of Primary Care Diagnosis Using Oscil...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.